Skip to main content
Premium Trial:

Request an Annual Quote

Arrayit Discloses Microarray Product Shipments to Illumina, Google

Premium

Arrayit recently announced that it had shipped microarray and other life sciences products to Illumina and Google.

The Sunnyvale, Calif.-based company, which sells instruments, tools, kits, and reagents, did not disclose the specific products that it shipped to its customers.

However, it did cite the "complementarity" of its array products with Illumina's noting in a statement that 100 publications feature the pairing of Arrayit and Illumina's array products.

Meantime, Arrayit called its relationship with Google a "natural fit," drawing parallels between the data processing requirements of both firms, and citing Google's investment in 23andMe, which uses Illumina-manufactured microarray products in its services.

Arrayit said it will report the proceeds from its sales to Illumina and Google when it announces its fourth quarter and full year 2013 earnings next year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.